International journal of radiation oncology, biology, physics 2013-05-01
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Abstract
Purpose
A multi-institutional phase 2 trial assessed the utility of dose-painted intensity modulated radiation therapy (DP-IMRT) in reducing grade 2+ combined acute gastrointestinal and genitourinary adverse events (AEs) of 5-fluorouracil (5FU) and mitomycin-C (MMC) chemoradiation for anal cancer by at least 15% compared with the conventional radiation/5FU/MMC arm from RTOG 9811.
Methods and materials
T2-4N0-3M0 anal cancer patients received 5FU and MMC on days 1 and 29 of DP-IMRT, prescribed per stage: T2N0, 42 Gy elective nodal and 50.4 Gy anal tumor planning target volumes (PTVs) in 28 fractions; T3-4N0-3, 45 Gy elective nodal, 50.4 Gy ≤ 3 cm or 54 Gy >3 cm metastatic nodal and 54 Gy anal tumor PTVs in 30 fractions. The primary endpoint is described above. Planned secondary endpoints assessed all AEs and the investigator's ability to perform DP-IMRT.
Results
Of 63 accrued patients, 52 were evaluable. Tumor stage included 54% II, 25% IIIA, and 21% IIIB. In primary endpoint analysis, 77% experienced grade 2+ gastrointestinal/genitourinary acute AEs (9811 77%). There was, however, a significant reduction in acute grade 2+ hematologic, 73% (9811 85%, P=.032), grade 3+ gastrointestinal, 21% (9811 36%, P=.0082), and grade 3+ dermatologic AEs 23% (9811 49%, P<.0001) with DP-IMRT. On initial pretreatment review, 81% required DP-IMRT replanning, and final review revealed only 3 cases with normal tissue major deviations.
Conclusions
Although the primary endpoint was not met, DP-IMRT was associated with significant sparing of acute grade 2+ hematologic and grade 3+ dermatologic and gastrointestinal toxicity. Although DP-IMRT proved feasible, the high pretreatment planning revision rate emphasizes the importance of real-time radiation quality assurance for IMRT trials.
Related Questions
Do you allow your CTV expansion to go into lung for IMRT esophagus cases or do you crop CTV expansion out of lung?
This is an excellent question and to be frank, the panelists that formulated the 2015 guidelines I authored did not consider this issue explicitly, hence the implication that lung should NOT be cropped out of the CTV. I certainly agree with the comments above that the lung per se is unlikely to repr...
When treating node positive anal squamous cell carcinoma, does your lymph node boost include only gross disease with margin or do you boost the entire nodal region?
First of all, I should note that, for purposes of RTOG 0529, there are eight nodal regions: mesorectal, presacral, right and left inguinal, R+L external iliac, and R + L internal iliac. So a patient with a clinically involved right inguinal node would only receive boost treatment on the right. The c...
Do you ever treat patients with rectal or anal cancer with IMRT in the prone position?
I would favor treating most patients with rectal and anal cancer in the prone position, with a bowel exclusion device incorporated into the immobilization. The RTOG 0529 small bowel DVH data suggest that, even with IMRT, there is at least a trend favoring the prone position. In my own practice, the ...
Can you skip elective inguinal treatment in PET negative squamous cell carcinoma of anal canal?
This is an interesting question. There are a few small series that suggest that the negative predictive value of a PET-CT may be quite high (100% in the study by Mistrangelo, IJROBP, 2012). However, the gold standard in these results was sentinel lymph node biopsy, not inguinal lymph node dissection...
How do you manage early stage anal or anal margin cancer that is locally excised with negative but close margins when going back for wider margins would require an APR?
I've seen this scenario several times when a patient has an excisional biopsy (the surgeon doesn't think it is cancer) and leaves behind a positive or close margin. After properly staging the patient with pelvic MRI, I typically recommend adjuvant chemoradiation since they are at risk for recurrence...
What dose do you typically prescribe to the primary tumor for definitive treatment of squamous cell carcinoma of the anal canal (given concurrently with chemotherapy)?
With IMRT: Primary TX and T1: 50 Gy/ 25 fx SIB to primary and 42 Gy microscopic T2: 54Gy /27 SIB and 45 Gy microscopic T3 58Gy /29 SIB and 47Gy microscopic T4 58Gy /29 SIB and 47Gy microscopic Nodes (all with no CTV/5mm PTV within the microscopic dose above): <2cm 50Gy SIB 2-5 cm 54Gy* SIB >5cm 5...